on October 23, 2003
Published online before print October 23, 2003, doi: 10.1161/01.ATV.0000102925.49136.52
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 18, 2003
Accepted on October 6, 2003
Soy Protein With Isoflavones, but not an Isoflavone-Rich Supplement, Improves Arterial Low-Density Lipoprotein Metabolism and Atherogenesis
Janice D. Wagner *;
From the Wake Forest University Medical Center, Winston-Salem, NC (J.D.W., L.Z., M.S.A., R.M.B., M.K.S., J.K.W.); Carl T. Hayden VA Medical Center, Phoenix, Ariz (D.C.S.); and Solae, LLC, St. Louis, Mo (K.A.G.).
* To whom correspondence should be addressed. E-mail: jwagner{at}wfubmc.edu.
Objective--We sought to determine if arterial LDL metabolism contributes to the decreased atherosclerosis seen with soy and if isolated isoflavones would have similar effects.
Methods and Results--Ovariectomized monkeys were fed an atherogenic diet for 20 weeks with a protein source of (1) casein/lactalbumin (CAS, n=20), (2) soy protein isolate (SOY, n=20), or (3) casein/lactalbumin with isolated soy isoflavones (ISO, n=17). Plasma lipoprotein concentrations were improved with SOY but not ISO. Arterial LDL metabolism was characterized with one subset (n=12/group) injected with dual-labeled tyramine-cellobiose (TC)-LDL (125I-TC-131I-LDL) 24 hours before necropsy to determine LDL degradation and accumulation, while another subset (n=8/group) was injected with 125I-TC-LDL 1 hour before necropsy to determine LDL permeability and delivery.
Conclusions--Coronary artery LDL degradation was reduced by 50% (P=0.02) with SOY but not with ISO compared with CAS. Neither treatment altered arterial permeability. Reduced LDL degradation with SOY was due to decreased arterial LDL delivery (P=0.02). Carotid artery cholesterol ester was also decreased with SOY, but not with ISO. Plasma isoprostanes or plasma markers of inflammation did not differ among treatment groups. Thus, the decreased arterial LDL delivery and subsequent LDL degradation may explain, in part, the atheroprotective effects of soy.
Key words: soy • isoflavones • atherosclerosis • lipoproteins • monkey
This article has been cited by other articles:
 |
|
 |
|
  A. Orgaard and L. Jensen The Effects of Soy Isoflavones on Obesity Experimental Biology and Medicine, September 1, 2008; 233(9): 1066 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-C. Yang, S.-M. Liu, H.-Y. Yang, Y.-H. Lin, and J.-R. Chen Soybean Protein Hydrolysate Improves Plasma and Liver Lipid Profiles in Rats Fed High-Cholesterol Diet J. Am. Coll. Nutr., October 1, 2007; 26(5): 416 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Peluso Flavonoids Attenuate Cardiovascular Disease, Inhibit Phosphodiesterase, and Modulate Lipid Homeostasis in Adipose Tissue and Liver Experimental Biology and Medicine, September 1, 2006; 231(8): 1287 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Adams, D. L. Golden, J. K. Williams, A. A. Franke, T. C. Register, and J. R. Kaplan Soy Protein Containing Isoflavones Reduces the Size of Atherosclerotic Plaques without Affecting Coronary Artery Reactivity in Adult Male Monkeys J. Nutr., December 1, 2005; 135(12): 2852 - 2856. [Abstract] [Full Text] [PDF]
|
|